Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

In the CodeBreaK 200 phase III, open-label trial, sotorasib significantly improved efficacy versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) for global health status, physical functioning, dyspnea, and cough favore...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: David Waterhouse, Sacha I. Rothschild, Christophe Dooms, B. Mennecier, Farastuk Bozorgmehr, Margarita Majem, Michel H. van den Heuvel, Helena Linardou, Byoung Chul Cho, Rachel Roberts‐Thomson, Kentaro Tanaka, Normand Blais, Gustavo Schvartsman, Karin Holmskov Hansen, Izabela Chmielewska, Martin Förster, Christina Giannopoulou, Björn Stollenwerk, Cynthia C. Obiozor, Yang Wang, Silvia Novello
Médium: Artigo
Jazyk:angličtina
Vydáno: 2024
On-line přístup:https://doi.org/10.1016/j.lungcan.2024.107921
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1016/j.lungcan.2024.107921

Podobné jednotky